Boston Scientific stock hits all-time high at 107.2 USD

July 01, 2025 04:15 AM AEST | By EODHD

Google News:

Boston Scientific stock hits all-time high at 107.2 USD — Image source: Kalkine Media

Recent News

Research Report on China-Indonesia Mangrove Protection under the Belt...

Asian Century: I Love You, Live On

HyperStrong and Repono forge strategic collaboration to advance grid-s...

Pioneering Global Presence, Empowering the World - Zuowei Technology S...

Boston Scientific Corp (NYSE:BSX)’s stock reached an all-time high of 107.2 USD, marking a significant milestone for the medical device company with a market capitalization of $158.5 billion. According to InvestingPro analysis, the stock appears to be trading above its Fair Value, with analysts setting price targets ranging from $86 to $135. This achievement reflects a robust 40.16% increase over the past year, showcasing the company’s strong performance and investor confidence. The surge in stock value underscores Boston Scientific’s successful strategies and market position, with impressive revenue growth of 19.4% and an overall Financial Health Score of "GREAT" from InvestingPro. The company continues to innovate and expand its product offerings in the healthcare sector, maintaining low price volatility and operating with moderate debt levels.

Investors are closely watching how the company will maintain this momentum amid evolving market conditions. For deeper insights, InvestingPro offers 13 additional tips and a comprehensive research report on Boston Scientific. In other recent news, Boston Scientific has confirmed its second-quarter and full-year 2025 guidance for both reported and organic sales, along with adjusted earnings per share (EPS). The company recently decided to halt global sales of its Acurate neo2 and Acurate Prime TAVR systems, following regulatory discussions that indicated the need for additional clinical requirements. Despite this discontinuation, Boston Scientific’s TAVR revenue outside the United States showed growth, reaching $214 million in 2024.

Piper Sandler maintains an Overweight rating on the company’s stock, highlighting the strong performance of the Farapulse system, which generated approximately $1 billion in its first year of U.S. commercial launch. Analysts from TD Cowen and Citi also maintain positive ratings, with price targets of $115 and $125, respectively, emphasizing the strategic focus on other investment opportunities. Needham analysts see potential growth from products like FARAPULSE and WATCHMAN, which may surpass consensus estimates. The CHAMPION trial results, expected in 2026, are anticipated to be a significant catalyst for the WATCHMAN device.

This strategic move by Boston Scientific is also seen as beneficial for competitors like Edwards Lifesciences (NYSE:EW), which may gain increased market share in the aortic valve sector. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.